EP3426301A4 - Nanoparticules composites et utilisations desdites nanoparticules - Google Patents

Nanoparticules composites et utilisations desdites nanoparticules Download PDF

Info

Publication number
EP3426301A4
EP3426301A4 EP17764049.7A EP17764049A EP3426301A4 EP 3426301 A4 EP3426301 A4 EP 3426301A4 EP 17764049 A EP17764049 A EP 17764049A EP 3426301 A4 EP3426301 A4 EP 3426301A4
Authority
EP
European Patent Office
Prior art keywords
composite nanoparticles
nanoparticles
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17764049.7A
Other languages
German (de)
English (en)
Other versions
EP3426301A1 (fr
Inventor
Peter Langecker
Matthias Steiert
Toshiaki Hino
Jan SCICINKSI
Kumarapandian PAULVANNAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Los Gatos Pharmaceuticals Inc
Original Assignee
Los Gatos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Gatos Pharmaceuticals Inc filed Critical Los Gatos Pharmaceuticals Inc
Publication of EP3426301A1 publication Critical patent/EP3426301A1/fr
Publication of EP3426301A4 publication Critical patent/EP3426301A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP17764049.7A 2016-03-08 2017-03-08 Nanoparticules composites et utilisations desdites nanoparticules Withdrawn EP3426301A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305526P 2016-03-08 2016-03-08
PCT/US2017/021452 WO2017156191A1 (fr) 2016-03-08 2017-03-08 Nanoparticules composites et utilisations desdites nanoparticules

Publications (2)

Publication Number Publication Date
EP3426301A1 EP3426301A1 (fr) 2019-01-16
EP3426301A4 true EP3426301A4 (fr) 2019-11-06

Family

ID=59787064

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17764049.7A Withdrawn EP3426301A4 (fr) 2016-03-08 2017-03-08 Nanoparticules composites et utilisations desdites nanoparticules

Country Status (4)

Country Link
US (2) US10064855B2 (fr)
EP (1) EP3426301A4 (fr)
JP (1) JP2019510085A (fr)
WO (1) WO2017156191A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156183A1 (fr) * 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Dérivés de camptothécine et leurs utilisations
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
ES2963150T3 (es) 2020-10-27 2024-03-25 Elucida Oncology Inc Procedimientos para funcionalizar nanopartículas
MX2024003496A (es) * 2021-10-15 2024-04-05 Kunshan Xinyunda Biotech Co Ltd Composicion que contiene un farmaco antitumoral, metodo de preparacion y uso de este.

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
EP0968711B9 (fr) 1997-10-28 2008-05-28 Bando Chemical Industries, Ltd. Feuille de timbre cutane et procede de production d'une feuille de base pour timbre
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
IN191203B (fr) 1999-02-17 2003-10-04 Amarnath Prof Maitra
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
DE10008904A1 (de) 2000-02-25 2001-09-06 Degussa Verfahren zur Rückgewinnung von Katalysator-Übergangsmetallen aus salzhaltigen Reaktionsgemischen
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6579519B2 (en) 2000-09-18 2003-06-17 Registrar, University Of Delhi Sustained release and long residing ophthalmic formulation and the process of preparing the same
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6834791B2 (en) 2002-01-24 2004-12-28 Nas Interplex Inc. Solder-bearing components and method of retaining a solder mass therein
US20060193902A1 (en) * 2003-04-02 2006-08-31 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
US20060083694A1 (en) * 2004-08-07 2006-04-20 Cabot Corporation Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same
EP1954246A4 (fr) * 2005-11-11 2012-01-18 Biolab Sanus Farmaceutica Ltda Composition pharmaceutique solide comprenant des nanoparticles d agglomerat et leur procede de production
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
US7993749B2 (en) 2005-12-16 2011-08-09 University Of Kansas Nanoparticles comprising a nanoparticle template and a polymer shell having an amide side chain, and method of making thereof
US20070202182A1 (en) * 2006-02-26 2007-08-30 Kane Kevin M Preparing solid formulation of nanoparticles of pharmaceutical ingredient, including at least micron-sized particles
WO2007145306A1 (fr) * 2006-06-15 2007-12-21 National University Corporation Hokkaido University Élément à temps de circulation sanguine prolongé sélectivement dégradable dans un tissu tumoral
CA2664919A1 (fr) * 2006-08-08 2008-02-21 Board Of Regents Of The University Of Texas Administration d'agents actifs a etapes multiples
EP2049545B1 (fr) 2006-08-11 2012-05-16 CHRISTUS Stehlin Foundation for Cancer Research Procédés de fabrication d'esters de camptothécines
US8414926B1 (en) 2006-09-12 2013-04-09 University Of South Florida Nanoparticles with covalently bound surfactant for drug delivery
CA2665343C (fr) 2006-10-05 2014-12-16 The Johns Hopkins University Formulations orales, parenterales et topiques dispersibles dans l'eau pour des medicaments faiblement solubles dans l'eau utilisant des nanoparticules polymeres intelligentes
LT2481402T (lt) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US20110038939A1 (en) * 2007-07-16 2011-02-17 Northeastern University Therapeutic stable nanoparticles
WO2009144775A1 (fr) * 2008-05-29 2009-12-03 Toto株式会社 Agent anti-tumoral
EP2153821A1 (fr) * 2008-08-06 2010-02-17 BioAlliance Pharma Formules orales de dérivés de camptothécine
WO2010048623A2 (fr) * 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Micro-agrégats médicaux et micro-agrégats d'imagerie
CA2752608A1 (fr) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Conjugues cytotoxiques ayant un compose de liaison au recepteur de neuropeptide y
US20130224282A1 (en) * 2010-09-21 2013-08-29 Massachusetts Institute Of Technology Multistage Nanoparticles
US20130101632A1 (en) * 2011-10-21 2013-04-25 University Of Kentucky Research Foundation Nanoparticulate formulations of mithramycin or mithramycin analogues for treating cancer
JP5673895B1 (ja) * 2013-03-13 2015-02-18 Dic株式会社 コア−シェル型ナノ粒子及びその製造方法
US11406714B2 (en) * 2013-08-21 2022-08-09 The Research Foundation For The State University Of New York Telodendrimers and nanocarriers and methods of using same
EP3068598A4 (fr) * 2013-10-24 2017-08-09 Srikar Raman Nanoparticules polymères monodispersées, nanoparticules fonctionnalisées et procédé de formation régulé
WO2015161273A1 (fr) * 2014-04-18 2015-10-22 Bind Therapeutics, Inc. Nanoparticules contenant du docétaxel pour le traitement de cancers présentant une mutation k-ras
US9668975B2 (en) * 2014-10-14 2017-06-06 PharmaDax Inc. Method of preparing drug agglomerate
WO2017156183A1 (fr) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Dérivés de camptothécine et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RONG TONG ET AL: "Controlled Synthesis of Camptothecin-Polylactide Conjugates and Nanoconjugates", BIOCONJUGATE CHEMISTRY, vol. 21, no. 1, 20 January 2010 (2010-01-20), US, pages 111 - 121, XP055616342, ISSN: 1043-1802, DOI: 10.1021/bc900356g *

Also Published As

Publication number Publication date
EP3426301A1 (fr) 2019-01-16
US20170258785A1 (en) 2017-09-14
US20180369232A1 (en) 2018-12-27
US10064855B2 (en) 2018-09-04
WO2017156191A1 (fr) 2017-09-14
JP2019510085A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
GB2554666B (en) Composite Particle
EP3253373A4 (fr) Nanoparticules de lipides et utilisations desdites nanoparticules
EP3253890A4 (fr) Agents de liaison à la tnfrsf et leurs utilisations
EP3358609A4 (fr) Feuille et feuille composite
EP3131853A4 (fr) Nanomatériaux et micro-matériaux composites, films associés, et procédés de fabrication et d'utilisation associés
EP3206740A4 (fr) Nébuliseurs et leurs utilisations
EP3357607A4 (fr) Feuille et feuille composite
EP3540008A4 (fr) Composition de résine, et structure multicouche mettant en uvre celle-ci
EP3281969A4 (fr) Corps formé à la presse et matériau composite
EP3122383B8 (fr) Nanostructures et leurs applications
EP3342684A4 (fr) Élément structurel et véhicule
EP3337719A4 (fr) Véhicules alimentés par le cycliste et mécanismes associés
EP3097128A4 (fr) Nanoparticules de polyamide et leurs utilisations
EP3308884A4 (fr) Corps de cuivre poreux et élément composite de cuivre poreux
EP3138827A4 (fr) Corps fritté composite
EP3264891A4 (fr) Etv2 et ses utilisations
EP3294392A4 (fr) Nébuliseurs et leurs utilisations
EP3242687A4 (fr) Nanoparticules et procédés pour leur préparation
EP3203986A4 (fr) Nanoparticules composites à base de stéarate de mg, procédés de préparation et applications
EP3089850A4 (fr) Corps composites et leurs procédés de formation
EP3533607A4 (fr) Élément composite
EP3279271A4 (fr) Composition et corps stratifié
EP3176235A4 (fr) Composition d'apprêt et objet composite
EP3138828A4 (fr) Corps fritté composite
GB201818517D0 (en) Nanoparticles and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LANGECKER, PETER

Inventor name: STEIERT, MATTHIAS

Inventor name: PAULVANNAN, KUMARAPANDIAN

Inventor name: SCICINKSI, JAN

Inventor name: HINO, TOSHIAKI

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191007

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/69 20170101ALI20190930BHEP

Ipc: A61K 31/47 20060101ALI20190930BHEP

Ipc: A61K 47/59 20170101ALI20190930BHEP

Ipc: A61K 9/51 20060101ALI20190930BHEP

Ipc: A61K 41/00 20060101AFI20190930BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200420

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200701